HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: An observational study

Clinical Infectious Diseases

Volumn 39, Issue SUPPL. 5, 2004, Pages

  Becker, Stephen ^a   Fusco, Gregory ^b   Fusco, Jennifer ^b   Balu, Rukmini ^b   Gangjee, Shehnaz ^b   Brennan, Clare ^b   Feinberg, Judith ^c  

^a Pacific Horizon Medical Group   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CD4 ANTIGEN; CIPROFLOXACIN; CLOFAZIMINE; CLOPIDOGREL; COTRIMOXAZOLE; CYCLOSPORIN; DIDANOSINE; ETHAMBUTOL; ETHINYLESTRADIOL; FLUCONAZOLE; MITOMYCIN; QUININE; TACROLIMUS; TICLOPIDINE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DRUG USE; FEMALE; FOLLOW UP; HEMOLYTIC UREMIC SYNDROME; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SINGLE-BLIND METHOD; UNITED STATES;

EID: 7444246754     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/422363     Document Type: Article

References (42)

1. Ruggenenti P, Norris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001; 60:831-46.
2. Ruggenenti P, Remuzzi G. The pathophysiology and management of thrombotic thrombocytopenic purpura. Eur J Haematol 1996; 56: 191-7.
3. Remuzzi G, Ruggenenti P. The hemolytic uremic syndrome. Kidney Int 1995; 48:2-19.
4. Kovacs MJ, Roddy J, Gregoire S, et al. TTP following hemorrhagic colitis due to E. coli O157:H7. Am J Med 1990; 88:177-9.
5. Tarr PI, Neill MA, Clausen CR, et al. Escherichia coli O157:H7 and the hemolytic syndrome: importance of early cultures in establishing the etiology. J Infect Dis 1990; 162:553-6.
6. Remuzzi G. HUS and TTP: variable expression of a single entity. Kidney Int 1987; 32:292-308.
7. Kaplan B. Thrombotic microangiopathy: a proposal for a new terminology for hemolytic syndrome and thrombotic thrombocytopenic purpura. J Nephrol 1995; 8:3-4.
8. National hospital discharge survey. Washington, DC: National Center for Health Statistics, 1990; series 13, no. 1.
9. Amorosi EL, Ultman JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of literature. Medicine 1966; 45:139-59.
10. Bell W, Braine H, Ness P, Kickler T. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: clinical experience in 108 patients. N Engl J Med 1991; 325:398-403.
11. Lara PN, Coe TL, Zhou H, et al. Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Am J Med 1999; 107:573-9.
12. Barz D, Budde U, Hellstern P. Therapeutic plasma exchange and plasma infusion in thrombotic microvascular syndromes. Thromb Res 2002; 107:523-7.
13. Andreoli SP. The pathophysiology of the hemolytic uremic syndrome. Curr Opin Nephrol Hypertens 1999; 8:459-64.
14. Neame PB. Immunologic and other factors in thrombotic thrombocytopenic purpura (TTP). Semin Thromb Hemost 1980; 6:416-29.
15. Musio F, Bohen EM, Yuan CM, et al. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum 1998; 28:1-19.
16. Lohrmann HP, Adam W, Heymer B, et al. Microangiopathic hemolytic anemia in metastatic carcinoma: report of eight cases. Ann Intern Med 1973; 79:368-75.
17. Lesesne JB, Rothschild N, Erickson B, et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989; 7:781-9.
18. Agarwal A, Mauer SM, Matas AJ, et al. Recurrent hemolytic uremic syndrome in an adult renal allograft recipient: current concepts and management. J Am Soc Nephrol 1995; 6:1160-9.
19. Powles RL, Clink HM, Spence D, et al. Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone marrow transplantation. Lancet 1980; 1:327-9.
20. Lacotte L, Thierry A, Delwail V, et al. Thrombotic thrombocytopenic purpura during Interferon alpha treatment for chronic myelogenous leukemia. Acta Haematol 2000; 102:160-2.
21. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med 1998; 128:541-4.
22. McDonald SP, Shanahan EM, Thomas AC, et al. Quinine-induced hemolytic uremic syndrome. Clin Nephrol 1997; 47:397-400.
23. McCarthy LJ, Porcu P, Fausel CA, et al. Thrombotic thrombocytopenic purpura and simvastatin. Lancet 1998; 352:1284-5.
24. Fahal IH, Williams PS, Clark RE, Bell GM. Thrombotic thrombocytopenic purpura due to rifampicin [case report]. BMJ 1992; 304:882.
25. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339:1578-84.
26. Tsai HM, Lian ECY. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339:1585-94.
27. Boccia R, Gelmann E, Baker C, Marti G, Longo DL. A hemolytic-uremic syndrome with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 101:716-7.
28. Leaf AN, Laubenstein LJ, Raphael B, et al. Thrombotic thrombocytopenic purpura associated with HIV-1 infection. Ann Intern Med 1988; 109:194-7.
29. Bachmeyer C, Blanche P, Sereni D, et al. Thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome in HIV-infected patients. AIDS 1995; 9:532-3.
30. Sutor BC, Schmidt RE, Albrecht H. Thrombotic microangiopathies and HIV infection: report of two typical cases, features of HUS and TTP, and review of the literature. Infection 1999; 27:12-5.
31. Bell W, Chulay J, Feinberg J. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine 1997; 76:369-80.
32. Peraldi MN, Maslo C, Descenclos JC, et al. Association between cytomegalovirus (CMV) infection and thrombotic microangiopathy (TMA) in HIV infected patients [abstract]. J Am Soc Nephrol 1995; 6:473.
33. Maslo C, Peraldi MN, Descenclos JC, et al. Thrombotic microangiopathy and cytomegalovirus disease in patients infected with human immunodeficiency virus. Clin Infect Dis 1997; 24:350-4.
34. Sahud MA, Claster S, Liu L, et al. von Willebrand factor-cleaving protease inhibitor in a patient with human immunodeficiency syndrome-associated thrombotic thrombocytopenic purpura. Br J Haematol 2002; 116:909-11.
35. del Arco A, Martinez MA, Pena JM, et al. Thrombotic thrombocytopenic purpura associated with human immunodeficiency virus infection; demonstration of p24 antigen in endothelial cells. Clin Infect Dis 1993; 17:360-3.
36. Gervasoni C, Ridolfo AL, Vaccarezza M, et al. Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy. Clin Infect Dis 2002; 35:1534-40.
37. Moore RD. Schistocytosis and a thrombotic microangiopathy-like syndrome in hospitalized HIV-infected patients. Am J Hematol 1999; 60: 116-20.
38. Becker SL, Raffanti SR, Hansen NI, et al. Zidovudine and stavudine sequencing in HIV treatment planning: findings from the CHORUS HIV cohort. J Acquir Immune Defic Syndr Hum Retrovirol 2001; 26: 72-81.
39. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600.
40. Feinberg J, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valacyclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. J Infect Dis 1998; 177:48-56.
41. Gadallah MF, el-Shahawy MA, Campese VM, Toff JR, King JW. Disparate prognosis of thrombotic microangiopathy in HIV-infected patients with and without AIDS. Am J Nephrol 1996; 16:446-50.
42. Fusco GP, Justice AC, Becker SL, et al. Strategies for obtaining consistent diagnoses for cause of death in an HIV observational cohort study [poster 5686]. Presented at: XIV International AIDS Conference, Barcelona, 7-12 July 2002.